FGFR2 and neoplasm: Both baseline tumor and tumor tissue at acquired resistance exhibited FGFR2 amplification, as determined by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) staining for FGFR2, which showed strong positivity in both the membrane and cytoplasm of tumor cells (Figure 2).